Tema Cardiovascular and Metabolic ETF
HRTS
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Brookfield Place, 200 Vesey Street, Suite 24106 New York NY United States of America 10281
- IPO Date
- Nov 21, 2023
- CIK
- 0001387131
- Website
- temaetfs.com
- Similar Companies
- Business
- Tema Cardiovascular and Metabolic ETF (HRTS) is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing primarily in equity securities of companies advancing treatments for cardiovascular diseases, metabolic disorders, obesity, diabetes, and related chronic conditions, including leaders in GLP-1 agonists, weight loss therapeutics, cardiometabolic innovations, and supporting healthcare services such as diagnostics, medical devices, and pharmaceuticals. The fund employs a bottom-up and top-down investment approach to select global holdings, with top positions typically including Eli Lilly and Co., UnitedHealth Group Inc., AstraZeneca PLC, Roche Holding AG, and Abbott Laboratories; it maintains a diversified portfolio across approximately 45 holdings, with roughly 81% in U.S. stocks, 18% in non-U.S. stocks, and minimal cash allocations. Launched on November 20, 2023, and domiciled in the United States, HRTS trades on the Nasdaq with assets under management of approximately $50 million to $52 million and a net expense ratio of 0.75%. The ETF targets the healthcare sector, specifically the health sub-category focused on large-cap blend styles, serving investors seeking exposure to the burgeoning obesity and cardiometabolic therapeutics market driven by genetic insights, regulatory advancements, and financing opportunities in high-risk biotechs. Geographic operations span global markets, with primary emphasis on U.S.-based issuers complemented by international exposure to Europe and other regions through holdings like Novo Nordisk A/S and AstraZeneca PLC. Managed by a team including Yuri Khodjamirian, Garrett Paolella, Troy Cates, Ryan Houlton, and David Song since inception, the fund is issued by Tema ETF Trust under Tema ETFs, part of Tema Global Limited. Recent developments include sustained asset growth to over $50 million amid heightened investor interest in weight loss drugs and cardiometabolic therapies as of late 2025, alongside portfolio adjustments reflecting strong performance in top holdings like Eli Lilly (up over 18%) and AstraZeneca (up 35%), with no major acquisitions, partnerships, or structural changes reported in the past 1-2 years. The fund has navigated market volatility, posting year-to-date gains and trading in the $29-$35 range in recent months, underscoring its focus on secular themes in obesity treatment and heart disease innovation without significant operational shifts or new product launches beyond ongoing active management.